Table 3.

Univariable and multivariable analysis for relapse and non-relapse mortality

NRelapseNRM
3-y (95% CI)HR (95% CI)*P*Adj HR (95% CI)†Adj P†3-y (95% CI)HR (95% CI)*P*Adj HR (95% CI)†Adj P†
Age, y            
 <40 65 0.31 (0.20, 0.43) Reference .22 Reference .53 0.20 (0.11, 0.31) Reference .41 Reference .55 
 ≥40 62 0.36 (0.24, 0.49) 1.45 (0.80, 2.62)  1.24 (0.64, 2.40)  0.29 (0.17, 0.41) 1.34 (0.65, 2.76)  1.26 (0.59, 2.68)  
Sex 
 M 77 0.29 (0.19, 0.40) Reference .20 Reference .14 0.26 (0.17, 0.37) Reference .26 Reference .41 
 F 50 0.40 (0.26, 0.54) 1.49 (0.82, 2.70)  1.60 (0.86, 2.95)  0.20 (0.09, 0.33) 0.66 (0.30, 1.45)  0.70 (0.30, 1.63)  
Cytogenetics            
 Good/intermediate 98 0.33 (0.24, 0.43) Reference .89 Reference .89 0.21 (0.13, 0.29) Reference .56 Reference .55 
 High 29 0.32 (0.16, 0.50) 1.06 (0.52, 2.17)  1.05 (0.51, 2.16)  0.37 (0.17, 0.57) 1.25 (0.58, 2.70)  1.28 (0.57, 2.87)  
Disease status at HCT 
 CR1 78 0.28 (0.18, 0.39) Reference .14 Reference .028 0.21 (0.12, 0.32) Reference .17 Reference .21 
 CR2/3 49 0.42 (0.27, 0.55) 1.60 (0.87, 2.92)  1.97 (1.07, 3.61)  0.29 (0.17, 0.42) 1.67 (0.81, 3.46)  1.60 (0.77, 3.33)  
MRD            
 Negative 76 0.32 (0.203, 0.44) Reference .92 Reference .92 0.28 (0.17, 0.39) Reference .73 Reference .80 
 Positive 13 0.31 (0.09, 0.57) 0.98 (0.32,2.98)  1.07 (0.31,3.64)  0.23 (0.05, 0.49) 0.84 (0.25, 2.78)  0.84 (0.23, 3.14)  
Donor type 
 MSD 41 0.38 (0.23, 0.53) Reference .81 Reference .96 0.21 (0.10, 0.36) Reference .076 Reference .019 
 MUD 37 0.25 (0.12, 0.40) 0.71 (0.33,1.50)  0.86 (0.39,1.89)  0.14 (0.05, 0.28) 0.67 (0.22, 2.04)  0.75 (0.22, 2.56)  
 mMUD 17 0.29 (0.10, 0.52) 0.80 (0.28,2.32)  0.83 (0.29,2.37)  0.38 (0.14, 0.63) 2.44 (0.93, 6.42)  3.60 (1.20, 10.83)  
 Haplo/cord 32 0.42 (0.21, 0.61) 0.94 (0.44,1.97)  1.03 (0.46,2.30)  0.31 (0.14, 0.49) 1.72 (0.67, 4.44)  1.97 (0.68, 5.71)  
Conditioning            
 MAC 87 0.32 (0.22, 0.43) Reference .14 Reference .028 0.23 (0.14, 0.33) Reference .46 Reference .80 
 RIC/NMA 40 0.36 (0.21, 0.51) 1.57 (0.86,2.86)  2.09 (1.08,4.02)  0.25 (0.13, 0.39) 1.28 (0.59, 2.77)  1.11 (0.50, 2.48)  
KPS 
 80-100 102 0.35 (0.23, 0.45) Reference .027 Reference .035 0.18 (0.11, 0.27) Reference <.001 Reference <.001 
 ≤70 15 0.07 (0.00, 0.27) 0.15 (0.02,1.16)  0.10 (0.01,0.85)  0.61 (0.30, 0.82) 5.28 (2.29, 12.13)  5.28 (2.29, 12.13)  
Ph-like            
 Other B-cell 71 0.31 (0.20, 0.42) Reference .47 Reference .24 0.25 (0.15, 0.36) Reference .76 Reference .99 
 Ph-like fusions 56 0.37 (0.24, 0.51) 1.23 (0.68, 2.23)  1.43 (0.79,2.61)  0.22 (0.12, 0.34) 1.10 (0.53, 2.28)  1.01 (0.48, 2.11)  
NRelapseNRM
3-y (95% CI)HR (95% CI)*P*Adj HR (95% CI)†Adj P†3-y (95% CI)HR (95% CI)*P*Adj HR (95% CI)†Adj P†
Age, y            
 <40 65 0.31 (0.20, 0.43) Reference .22 Reference .53 0.20 (0.11, 0.31) Reference .41 Reference .55 
 ≥40 62 0.36 (0.24, 0.49) 1.45 (0.80, 2.62)  1.24 (0.64, 2.40)  0.29 (0.17, 0.41) 1.34 (0.65, 2.76)  1.26 (0.59, 2.68)  
Sex 
 M 77 0.29 (0.19, 0.40) Reference .20 Reference .14 0.26 (0.17, 0.37) Reference .26 Reference .41 
 F 50 0.40 (0.26, 0.54) 1.49 (0.82, 2.70)  1.60 (0.86, 2.95)  0.20 (0.09, 0.33) 0.66 (0.30, 1.45)  0.70 (0.30, 1.63)  
Cytogenetics            
 Good/intermediate 98 0.33 (0.24, 0.43) Reference .89 Reference .89 0.21 (0.13, 0.29) Reference .56 Reference .55 
 High 29 0.32 (0.16, 0.50) 1.06 (0.52, 2.17)  1.05 (0.51, 2.16)  0.37 (0.17, 0.57) 1.25 (0.58, 2.70)  1.28 (0.57, 2.87)  
Disease status at HCT 
 CR1 78 0.28 (0.18, 0.39) Reference .14 Reference .028 0.21 (0.12, 0.32) Reference .17 Reference .21 
 CR2/3 49 0.42 (0.27, 0.55) 1.60 (0.87, 2.92)  1.97 (1.07, 3.61)  0.29 (0.17, 0.42) 1.67 (0.81, 3.46)  1.60 (0.77, 3.33)  
MRD            
 Negative 76 0.32 (0.203, 0.44) Reference .92 Reference .92 0.28 (0.17, 0.39) Reference .73 Reference .80 
 Positive 13 0.31 (0.09, 0.57) 0.98 (0.32,2.98)  1.07 (0.31,3.64)  0.23 (0.05, 0.49) 0.84 (0.25, 2.78)  0.84 (0.23, 3.14)  
Donor type 
 MSD 41 0.38 (0.23, 0.53) Reference .81 Reference .96 0.21 (0.10, 0.36) Reference .076 Reference .019 
 MUD 37 0.25 (0.12, 0.40) 0.71 (0.33,1.50)  0.86 (0.39,1.89)  0.14 (0.05, 0.28) 0.67 (0.22, 2.04)  0.75 (0.22, 2.56)  
 mMUD 17 0.29 (0.10, 0.52) 0.80 (0.28,2.32)  0.83 (0.29,2.37)  0.38 (0.14, 0.63) 2.44 (0.93, 6.42)  3.60 (1.20, 10.83)  
 Haplo/cord 32 0.42 (0.21, 0.61) 0.94 (0.44,1.97)  1.03 (0.46,2.30)  0.31 (0.14, 0.49) 1.72 (0.67, 4.44)  1.97 (0.68, 5.71)  
Conditioning            
 MAC 87 0.32 (0.22, 0.43) Reference .14 Reference .028 0.23 (0.14, 0.33) Reference .46 Reference .80 
 RIC/NMA 40 0.36 (0.21, 0.51) 1.57 (0.86,2.86)  2.09 (1.08,4.02)  0.25 (0.13, 0.39) 1.28 (0.59, 2.77)  1.11 (0.50, 2.48)  
KPS 
 80-100 102 0.35 (0.23, 0.45) Reference .027 Reference .035 0.18 (0.11, 0.27) Reference <.001 Reference <.001 
 ≤70 15 0.07 (0.00, 0.27) 0.15 (0.02,1.16)  0.10 (0.01,0.85)  0.61 (0.30, 0.82) 5.28 (2.29, 12.13)  5.28 (2.29, 12.13)  
Ph-like            
 Other B-cell 71 0.31 (0.20, 0.42) Reference .47 Reference .24 0.25 (0.15, 0.36) Reference .76 Reference .99 
 Ph-like fusions 56 0.37 (0.24, 0.51) 1.23 (0.68, 2.23)  1.43 (0.79,2.61)  0.22 (0.12, 0.34) 1.10 (0.53, 2.28)  1.01 (0.48, 2.11)  

Adj, adjusted; MAC, myeloablative conditioning.

*

Univariate analysis and Gray’s test.

†

Based on the multivariable Fine and Gray regression model adjusted for disease status, conditioning, and KPS for relapse. Donor type and KPS were adjusted for NRM.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal